Please provide your email address to receive an email when new articles are posted on . Results from a recent phase 3 study showed that Resolor is a safe, effective and well-tolerated treatment for ...

Resolor is the first of a new generation of selective, high-affinity 5-HT4 receptor agonists. The product was approved in the EU by the European Medicines Agency (“EMA”) in October 2009 for the ...

TURNHOUT, Belgium, May 29 /PRNewswire/ -- Movetis today announced that the European Medicines Agency (EMeA) has accepted the Marketing Authorization Application (MAA) submission for RESOLOR(R) ...

Quintiles today announced a strategic alliance with Movetis NV for commercialization of its new product, Resolor (prucalopride), in the U.K. and Germany. Under the alliance, Quintiles will execute a ...

The latest set of opinions from the European Medicines Agency’s Committee for Medicinal Products for Human Use includes a number of extensions of indication and a recommendation for a new orphan drug.

BRUSSELS, Nov 20 (Reuters) - Belgian drugmaker Movetis said it could raise up to 112.4 million euros ($167 million) in an initial public offering to help fund the European launch of its Resolor ...

Shire acquired the rights Tuesday to develop and market the constipation drug Resolor in the United States in an agreement with Janssen Pharmaceutica. Terms of the deal were not disclosed. Resolor is ...

LONDON (Alliance News) - FTSE 100-listed pharmaceutical company Shire PLC said Wednesday that the European Medicines Agency has approved Resolor for the use in male adults for the treatment of chronic ...

Shire ( SHPGY) recently announced that it has entered into an agreement with Janssen Pharmaceutica N.V., a Johnson & Johnson ( JNJ) company, to acquire the rights to develop and commercialize Resolor ...

medication, primarily because of a lack of efficacy. weeks of the study. A bowel movement was defined as spontaneous if no laxatives were taken in the 24 hours preceding the bowel movement.